Across 60 studies encompassing 1,250,717 individuals — including 46 randomized controlled trials — GLP-1 receptor agonists produced a statistically significant and robust reduction in lean body mass/fat-free mass (SMD 0.52, 95% CI −0.8 to −0.23), driven primarily by semaglutide and liraglutide versus placebo. No meaningful effects on bone mineral density, fracture risk, or WOMAC joint pain or physical function scores emerged when the most-adjusted effect estimates were applied. Bone and joint outcomes were essentially neutral.
The muscle loss finding is clinically consequential and lands in already-turbulent waters. GLP-1 agonists are now prescribed to tens of millions globally, yet this meta-analysis confirms what smaller trials have hinted at: a meaningful fraction of weight lost on these drugs comes from lean tissue, not just fat. Preserving muscle mass is a cornerstone of healthy aging — low muscle mass independently predicts falls, fractures, metabolic dysfunction, and all-cause mortality. The irony is stark: drugs prescribed for metabolic disease may simultaneously accelerate sarcopenia, a condition that amplifies that same disease burden. Importantly, this analysis cannot fully disentangle whether muscle loss is drug-driven or caloric-restriction-driven, a critical mechanistic gap. Resistance training and adequate protein intake are likely essential co-interventions but remain understudied in this context. The GRADE-assessed evidence is heterogeneous (I² = 88%), limiting precision. Still, the consistency across sensitivity analyses elevates this from a signal to a genuine clinical concern warranting mandatory lifestyle co-prescription guidance.